Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.

doi:10.1158/1078-0432.CCR-24-0226

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2024

Slater Susanna, Bryant Annette, Aresu Maria, Begum Ruwaida, Chen Hsiang-Chi, Peckitt Clare, Lazaro-Alcausi Retchel, Carter Paul, Anandappa Gayathri, Khakoo Shelize, Melcher Lucinda, Potter Vanessa, Marti Francisca M, Huang Joesph, Branagan Graham, George Nicol, Abulafi Muti, Duff Sarah, Raja Ashraf, Gupta Ashish, West Nicholas, Bucheit Leslie, Rich Thereasa, Chau Ian, Cunningham David, Starling Naureen

Abstract excerpt

PURPOSE: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) with low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest resected CRC cohort to date with tissue-free minimal residual disease (MRD) detection. EXPERIMENTAL DESIGN: TRACC (tracking mutations in cell-free tumor DNA to predict relapse in early...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to DNA Methylation

Share to Liquid Biopsy

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Neoplasm Staging

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 38864835
DOI: 10.1158/1078-0432.CCR-24-0226
PMCID: PMC11325146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.PMID 38864835Read ↗

Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)Semantic proximity Read ↗

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerSemantic proximity Read ↗

Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease AssaySemantic proximity Read ↗

Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.Semantic proximity Read ↗

Ultrasensitive tumour‐agnostic non‐invasive detection of colorectal cancer recurrence using ctDNA methylationSemantic proximity Read ↗

Molecular residual disease detection by serial tumour-informed circulating tumour DNA analysis in resectable oesophageal & gastroesophageal junctional adenocarcinoma: a prospective UK multi-centre studySemantic proximity Read ↗

Minimal residual disease detection with circulating tumor DNA in colorectal cancer: current horizons and future perspectives in clinical applicationsSemantic proximity Read ↗

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.Semantic proximity Read ↗

Beyond Binary MRD: Quantitative ctDNA Interpretation After Curative-Intent Surgery for Colorectal CancerSemantic proximity Read ↗

Using ctDNA to Predict Recurrence After Surgery in Stage II–III Colorectal Cancer: A Systematic Review and Narrative Meta-AnalysisSemantic proximity Read ↗

Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.Semantic proximity Read ↗

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.